Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials

OBJECTIVES: The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Antimicrob Chemother
Autori principali: Nelson, Mark, Amaya, Gerardo, Clumeck, Nathan, Arns da Cunha, Clovis, Jayaweera, Dushyantha, Junod, Patrice, Li, Taisheng, Tebas, Pablo, Stevens, Marita, Buelens, Annemie, Vanveggel, Simon, Boven, Katia
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2012
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643643/
https://ncbi.nlm.nih.gov/pubmed/22532465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dks130
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi